CL2020002680A1 - Anticuerpos para radionúclidos quelados - Google Patents
Anticuerpos para radionúclidos queladosInfo
- Publication number
- CL2020002680A1 CL2020002680A1 CL2020002680A CL2020002680A CL2020002680A1 CL 2020002680 A1 CL2020002680 A1 CL 2020002680A1 CL 2020002680 A CL2020002680 A CL 2020002680A CL 2020002680 A CL2020002680 A CL 2020002680A CL 2020002680 A1 CL2020002680 A1 CL 2020002680A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- chelated radionuclides
- relates
- furthermore
- bispecific antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Detergent Compositions (AREA)
Abstract
La presente solicitud se refiere a anticuerpos que se unen específicamente a radionúclidos quelados, incluyendo anticuerpos biespecíficos. Además, se refiere al uso de dichos anticuerpos biespecíficos en aplicaciones tales como la radioinmunoimagen y la radioinmunoterapia. Además, se refiere a agentes de depuración y composiciones útiles en tales métodos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658468P | 2018-04-16 | 2018-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002680A1 true CL2020002680A1 (es) | 2021-02-12 |
Family
ID=66476592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002680A CL2020002680A1 (es) | 2018-04-16 | 2020-10-16 | Anticuerpos para radionúclidos quelados |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20220389116A1 (es) |
| EP (2) | EP4406607A3 (es) |
| JP (3) | JP7475283B2 (es) |
| KR (1) | KR102884852B1 (es) |
| CN (1) | CN112261952A (es) |
| AR (1) | AR115053A1 (es) |
| AU (1) | AU2019254537B2 (es) |
| BR (1) | BR112020021061A2 (es) |
| CA (1) | CA3096338A1 (es) |
| CL (1) | CL2020002680A1 (es) |
| CR (1) | CR20200548A (es) |
| DK (1) | DK3781200T3 (es) |
| ES (1) | ES2985352T3 (es) |
| FI (1) | FI3781200T3 (es) |
| HR (1) | HRP20241013T1 (es) |
| HU (1) | HUE067622T2 (es) |
| IL (1) | IL277575B2 (es) |
| LT (1) | LT3781200T (es) |
| MA (1) | MA52545B1 (es) |
| MX (1) | MX2020010954A (es) |
| MY (1) | MY207044A (es) |
| PE (1) | PE20210442A1 (es) |
| PL (1) | PL3781200T3 (es) |
| PT (1) | PT3781200T (es) |
| RS (1) | RS65753B1 (es) |
| SG (1) | SG11202010066TA (es) |
| SI (1) | SI3781200T1 (es) |
| TW (1) | TWI874314B (es) |
| UA (1) | UA130541C2 (es) |
| WO (1) | WO2019201959A1 (es) |
| ZA (1) | ZA202006121B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| IL298921A (en) * | 2020-07-10 | 2023-02-01 | Hoffmann La Roche | Antibodies that bind to cancer cells and direct radionuclides to said cells |
| JP2024504931A (ja) | 2021-01-12 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体 |
| CN116744981A (zh) * | 2021-01-13 | 2023-09-12 | 豪夫迈·罗氏有限公司 | 组合疗法 |
| US20240173442A1 (en) | 2021-01-13 | 2024-05-30 | Hoffmann-La Roche Inc. | Combination therapy |
| TW202330592A (zh) | 2021-12-15 | 2023-08-01 | 美商Ｙ單克隆抗體製藥有限公司 | 具有經減少之多聚化(MULTIMERISATION)的scFv及抗體 |
| TW202434650A (zh) | 2022-11-08 | 2024-09-01 | 美商Ｙ單克隆抗體製藥有限公司 | 雙特異性抗體化合物 |
| WO2025176614A1 (en) | 2024-02-20 | 2025-08-28 | F. Hoffmann-La Roche Ag | Novel pre-targeting antibodies and uses thereof |
| WO2026041568A1 (en) | 2024-08-20 | 2026-02-26 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and dotam |
| WO2026082710A1 (en) | 2024-10-16 | 2026-04-23 | F. Hoffmann-La Roche Ag | Small molecule-inducible recombinant receptors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201608192SA (en) * | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| JP6912379B2 (ja) | 2014-12-23 | 2021-08-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物 |
| KR20170110601A (ko) * | 2015-02-05 | 2017-10-11 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물 |
| EP3256164B1 (en) * | 2015-02-09 | 2020-03-25 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex |
| KR20180073561A (ko) * | 2015-10-02 | 2018-07-02 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자 |
| EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
| ES3054945T3 (en) | 2018-04-16 | 2026-02-09 | Orano Med Mfg Sas | Antibodies for chelated radionuclides and clearing agents |
-
2019
- 2019-04-16 LT LTEPPCT/EP2019/059856T patent/LT3781200T/lt unknown
- 2019-04-16 CR CR20200548A patent/CR20200548A/es unknown
- 2019-04-16 PL PL19723014.7T patent/PL3781200T3/pl unknown
- 2019-04-16 TW TW108113285A patent/TWI874314B/zh active
- 2019-04-16 IL IL277575A patent/IL277575B2/en unknown
- 2019-04-16 MA MA52545A patent/MA52545B1/fr unknown
- 2019-04-16 PT PT197230147T patent/PT3781200T/pt unknown
- 2019-04-16 CA CA3096338A patent/CA3096338A1/en active Pending
- 2019-04-16 CN CN201980038709.1A patent/CN112261952A/zh active Pending
- 2019-04-16 BR BR112020021061-7A patent/BR112020021061A2/pt unknown
- 2019-04-16 JP JP2020556869A patent/JP7475283B2/ja active Active
- 2019-04-16 HU HUE19723014A patent/HUE067622T2/hu unknown
- 2019-04-16 MY MYPI2020005339A patent/MY207044A/en unknown
- 2019-04-16 AU AU2019254537A patent/AU2019254537B2/en active Active
- 2019-04-16 EP EP24169799.4A patent/EP4406607A3/en active Pending
- 2019-04-16 DK DK19723014.7T patent/DK3781200T3/da active
- 2019-04-16 AR ARP190101005A patent/AR115053A1/es unknown
- 2019-04-16 RS RS20240810A patent/RS65753B1/sr unknown
- 2019-04-16 ES ES19723014T patent/ES2985352T3/es active Active
- 2019-04-16 PE PE2020001551A patent/PE20210442A1/es unknown
- 2019-04-16 UA UAA202007212A patent/UA130541C2/uk unknown
- 2019-04-16 FI FIEP19723014.7T patent/FI3781200T3/fi active
- 2019-04-16 MX MX2020010954A patent/MX2020010954A/es unknown
- 2019-04-16 US US17/048,073 patent/US20220389116A1/en not_active Abandoned
- 2019-04-16 KR KR1020207032824A patent/KR102884852B1/ko active Active
- 2019-04-16 HR HRP20241013TT patent/HRP20241013T1/hr unknown
- 2019-04-16 SI SI201930792T patent/SI3781200T1/sl unknown
- 2019-04-16 WO PCT/EP2019/059856 patent/WO2019201959A1/en not_active Ceased
- 2019-04-16 EP EP19723014.7A patent/EP3781200B1/en active Active
- 2019-04-16 SG SG11202010066TA patent/SG11202010066TA/en unknown
-
2020
- 2020-10-02 ZA ZA2020/06121A patent/ZA202006121B/en unknown
- 2020-10-16 CL CL2020002680A patent/CL2020002680A1/es unknown
-
2024
- 2024-01-12 JP JP2024003062A patent/JP2024056687A/ja not_active Withdrawn
-
2025
- 2025-09-18 US US19/333,297 patent/US20260015436A1/en active Pending
- 2025-12-10 JP JP2025244101A patent/JP2026062683A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210442A1 (es) | Anticuerpos para radionuclidos quelados | |
| CL2019003657A1 (es) | Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275) | |
| MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| MX373245B (es) | Anticuerpos cd3 humanizados o quiméricos. | |
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| CU20210096A7 (es) | Moléculas de unión a cd19 | |
| CL2019003800A1 (es) | Métodos para tratar la enfermedad de huntington. | |
| ECSP18005520A (es) | Anticuerpos de factor xi y métodos de uso | |
| CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| UY37083A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso | |
| MX2017014136A (es) | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. | |
| MX2016001236A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CO2022008272A2 (es) | Agentes de unión a ilt3 y métodos de uso de los mismos | |
| WO2019202399A8 (en) | Antibodies for chelated radionuclides and clearing agents | |
| UY37258A (es) | AGENTES REVERSORES DE UNIÓN PARA ANTICUERPOS ANTI-FACTOR XI/XIa Y SUS USOS | |
| GT201500349A (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| EA201992027A1 (ru) | Водный состав антитела против pd-l1 | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| EA201591389A1 (ru) | Косметические композиции с трициклодеканамидами |